Antibody Therapy Reprograms Suppressive Regulatory T Cells Into Cancer Killers in Myeloma
Researchers discovered that bispecific T-cell engager therapy reprograms immunosuppressive regulatory T cells into cancer-killing cells in patients with multiple myeloma.



